The event will see speakers from Roche, AstraZeneca, Ionis, Silence Therapeutics, Oxford University, Inserm, UCSD, Sixfold (and others) converge at the Astra Zeneca site in Gothenburg for three days, from Tuesday 9th to Thursday 11th of May, 2023.

Sixfold Bioscience team lead of Structure & Characterization, Dr. Alice Ghidini, will be presenting her talk on “‘Harnessing RNA-protein binding for nucleic acids therapeutics design improvement” at 11:10 am CET on Tuesday 9th.

This years’ themes are:

• Therapeutic oligo profiling and advancements in oligo design and synthesis
• Novel formulations and biomarker analysis
• Chemical probe-induced protein interaction and degradation
• New ways to shape and interrogate biology through chemistry

‍

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on siRNA and ASO.

Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.